Unlike previous traditional pairwise meta-analyses, which either found a higher risk [2,3,4] or no significant risk difference [5,6,7] for primary cancers, our NMA focused on metastatic cancers and observed a significantly prophylactic effect on the incidence of metastatic cancers by efpeglenatide, but no other GLP-1 receptor agonists or SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is metastatic malignant neoplasm.